Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-Term Opioid Use More Common in Hidradenitis Suppurativa

Publish date:: October 14, 2019

Key clinical point: Patients with hidradenitis suppurativa (HS) are at an increased risk of long-term opioid use.

Major finding: Patients with HS were more likely to use opioids for at least a year, compared with a control group (adjusted odds ratio, 1.53, 95% confidence interval, 1.20-1.95; P less than .001).

Study details: Retrospective analysis of nearly 829,000 patients in a control group and 22,277 with HS who were tracked over a 10-year period.

Disclosures: An educational grant to a study author from AbbVie partially funded the study. No other study funding is reported. The lead author had no disclosures; one author disclosed having received grants and personal fees from AbbVie and UCB during the study.

Citation:

Reddy S et al. JAMA Dermatol. 2019 Sep 11. doi: 10.1001/jamadermatol.2019.2610.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Dermatology

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Study results support screening rosacea patients for cardiometabolic disease,

Phase 1 study: Beta-blocker may improve melanoma treatment response,

Baricitinib reduces adult atopic dermatitis severity in phase 3 study,

New lupus classification criteria perform well in children, young adults,